The international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma. Patients were treated at 130 medical centers ...

Noninferiority of subcutaneous nivolumab to IV Opdivo was shown for the time-averaged serum concentration over the first 28 days, with a geometric mean ratio of 2.098.

Opdivo is a programmed death receptor-1 blocking antibody. (Credit: Getty Images.) The Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for the adjuvant treatment of completely ...

Currently, Opdivo is approved in an intravenous (IV) form, which involves administering the drug to a vein over a period of time. The subcutaneous method can be done quicker compared with IV treatment ...

Opdivo, Bristol Myers’ PD-1 immune checkpoint inhibitor, was initially approved in 2014 to treat patients (IV-ly) with unresectable or metastatic melanoma and disease progression following ...

Individuals enrolled in one of the study’s three pretreated patient cohorts will receive three mg/kg of Opdivo as an IV injection every two weeks. The treatment-naïve patient cohort will receive 240 ...

US Food and Drug Administration approves Opdivo® (nivolumab) as adjuvant treatment for eligible patients with completely resected stage IIB or stage IIC melanoma. Bristol Myers Squibb. October 13 ...

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) ;Opdivo for ...

Opdivo demonstrated an 18-month RFS rate of 66.4% (95% CI: 61.8 to 70.6) compared with 52.7% for Yervoy (95% CI: 47.8 to 57.4), with the median RFS not yet determined in either group.

Oct 19 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Thursday the injectable form of its blockbuster cancer drug Opdivo met the main goal in trial that had patients with a type ...

Nivolumab alone or in combination with ipilimumab was safe and well-tolerated in patients with resectable hepatocellular carcinoma in the perioperative setting, according to a study published in ...

Opdivo and Keytruda have other uses as well. In addition, the two drugs are both biologic medications. There aren’t biosimilar versions of either drug available. Brand-name medications are often ...